The tumour suppressor p53 has been shown to regulate RNA polymerase (pol) III transcription both in vitro and in vivo. We have characterized the regions of p53 that contribute to this effect. Repression of pol III transcription in vivo does not require residues 13 -19 near the Nterminus of p53 that are highly conserved through evolution. However, amino acids 22 and 23 in the adjacent transactivation domain do contribute to the inhibition of pol III activity. Deletions within the central DNA-binding core domain (residues 102 -292) of p53 can entirely abolish the repression function in these assays, despite the fact that pol III templates contain no recognized p53 binding site. Deletion or substitution within the C-terminal domain of p53 can also compromise its ability to repress pol III activity in vitro and in transfected cells. These observations reveal that repression of pol III transcription is a complex function involving multiple regions of p53 extending throughout much of the protein.
Introduction
The ability of cells to reduce macromolecular synthesis whilst concurrently activating stress-response genes provides an essential defence against environmental insults. The p53 protein is a key player in this protective response in higher organisms (Cox and Lane, 1995; Ko and Prives, 1996; Levine, 1997; Sionov and Haupt, 1999; Vogelstein et al., 2000; Vousden, 2000) . Under a range of physiological stress conditions, p53 can induce either cell cycle arrest or apoptosis, depending on circumstances (Cox and Lane, 1995; Ko and Prives, 1996; Levine, 1997; Sionov and Haupt, 1999; Vogelstein et al., 2000; Vousden, 2000) . The arrest function provides an opportunity to repair damaged DNA before it is replicated and passed on to daughter cells. Apoptosis offers an alternative route for ensuring that damage is not perpetuated amongst cellular progeny. Most tumours evade these defences by inactivating p53 (Cox and Lane, 1995; Hollstein et al., 1991 Hollstein et al., , 1994 Ko and Prives, 1996; Levine, 1997; Sionov and Haupt, 1999; Vogelstein et al., 2000; Vousden, 2000) .
The effectiveness of p53 in this protective role stems largely from its ability to regulate batteries of genes (Crook et al., 1994; Ko and Prives, 1996; Pietenpol et al., 1994) . A well-characterized example is the p21/ WAF1/CIP1 gene, which is activated by p53 and plays an important role in G1 arrest (El-Deiry et al., 1993) . The transcriptional activation function of p53 involves sequence-specific binding to promoter DNA (Farmer et al., 1992; Kern et al., 1991; Zambetti et al., 1992) . In addition, p53 can repress certain genes that lack its DNA recognition site (Avantaggiati et al., 1997; Cairns and White, 1998; Chen et al., 1992; Chesnokov et al., 1996; Crook et al., 1994; Ginsberg et al., 1991; Horikoshi et al., 1995; Mack et al., 1993; Murphy et al., 1996 Murphy et al., , 1999 Ragimov et al., 1993; Seto et al., 1992; Subler et al., 1994; Yu et al., 1999; Zhao et al., 2000) . It is sometimes argued that this repression is relatively non-specific, since it occurs in the absence of a p53-binding DNA sequence; however, a microarray analysis found that only 0.9% of the *6000 genes examined were inhibited by p53, whereas 1.8% were induced (Zhao et al., 2000) . Since some of the genes that are repressed by p53 encode growth-promoting products, it has been suggested that the transcriptional repression activity may contribute towards the antiproliferative properties of p53 (Cox and Lane, 1995; Ko and Prives, 1996; Neufeld and Edgar, 1998) . This possibility is supported by the fact that many p53 point mutants which are unable to inhibit transcription have also lost the capacity to suppress cell growth (Chen et al., 1992; Crook et al., 1994; Ginsberg et al., 1991; Ragimov et al., 1993; Seto et al., 1992) . Furthermore, two oncoproteins were found to block specifically the repression function of p53, without affecting its ability to activate expression (Shen and Shenk, 1994) .
Genes transcribed by RNA polymerase (pol) III provide an abundant class of template that is repressed by p53 both in vitro and in vivo (Cairns and White, 1998; Chesnokov et al., 1996) . Overexpression of p53 can repress pol III transcription in transfected cells (Chesnokov et al., 1996) , whilst synthesis of tRNA and 5S rRNA by pol III is elevated significantly in fibroblasts derived from p53 knockout mice (Cairns and White, 1998) . These effects result from the ability of p53 to bind directly to the pol III-specific factor TFIIIB and suppress its activity (Cairns and White, 1998; Chesnokov et al., 1996) . Thus, a stable interaction between TFIIIB and recombinant or endogenous p53 has been demonstrated using cofractionation, coimmunoprecipitation and pull-down assays (Cairns and White, 1998; Chesnokov et al., 1996) . In reconstituted transcription experiments, recombinant p53 inactivates TFIIIB with a high degree of specificity (Cairns and White, 1998) . Furthermore, p53 knockout fibroblasts display abnormally elevated TFIIIB activity when compared with matched wildtype controls (Cairns and White, 1998) . Since sustained growth requires high levels of pol III products, such as tRNA and 5S rRNA, the ability of p53 to repress TFIIIB may contribute towards its growth-restraining capacity.
The current study has extended the previous analyses in order to characterize which regions of p53 contribute to its ability to regulate the pol III system. We demonstrate that the central DNA-binding domain is necessary, despite the fact that genes transcribed by pol III rarely contain sequences that resemble the p53 recognition motif. Regions both N-and C-terminal to the central core domain are also involved in repression of pol III transcription, both in vitro and in vivo.
Residues near the N-terminus of p53 that are important for controlling pol III coincide with the region that is known to mediate transactivation or repression of pol II templates. Deletion of the Cterminal domain abolishes the ability of p53 to inhibit pol III transcription. The repression function can also be compromised by substitution within this region. We conclude that at least three distinct regions of p53 contribute to its capacity to regulate transcription by pol III.
Results
The central domain of p53 is required for repression of pol III transcription p53 is generally well conserved through vertebrate evolution, but this is especially true of five regions that are almost identical from trout to man (Soussi et al., 1990) . Of these, region I lies near the N-terminus, whilst regions II -V are all located within the central core domain (residues 102 -292) that is essential for specific DNA binding (Figure 1a ). Since the conserved regions are most likely to be responsible for the important functions of p53, we tested whether they contribute to its ability to repress pol III transcription in vivo. We made use of a series of five mutant expression constructs in which the conserved regions had been deleted individually; these were transfected into the p53-negative osteosarcoma cell line SAOS2, as were the equivalent construct expressing wild-type p53 and empty vector, as positive and negative controls, respectively. Each of the mutants is stably expressed in SAOS2 cells (Kubbutat et al., 1998) . As a reporter for pol III activity we transfected the adenovirus VA1 gene, as this has an internal promoter which is extremely well characterized and is representative of the majority of pol III templates, including tRNA genes (Paule and White, 1998a) . As an internal control for transfection efficiency and RNA recovery, we cotransfected a reporter carrying HSV -CAT, in which the chloramphenicol acetyltransferase gene is transcribed from the basal thymidine kinase promoter of herpes simplex virus. Production of RNA from the VA1 and HSV -CAT reporters was then determined by quantitative primer extension assays. A representative example of such experiments is shown in Figure 1b . It is clear that wild-type p53 represses the pol III-dependent expression of VA1, when compared with the empty vector ( Figure 1b , top panel); this effect is specific, since the pol II reporter HSV -CAT is not inhibited (Figure 1b , middle panel). Efficient and specific repression of VA1 is also obtained using the . RNA and protein were isolated 48 h after transfection. The upper and second panels show primer extension analyses of extracted RNA using primers specific for VA1 (upper panel) and CAT (middle panel). The third panel shows a Western blot of extracted protein using anti-p53 antibody DO-1; the p53DI mutant is not detected because this deletion disrupts the epitope recognized by DO-1. Expression of p53DI is therefore confirmed in the bottom panel using antibody PAb421
Domains used by p53 to repress pol III transcription T Stein et al DI mutant, in which the N-terminal conserved region has been deleted. Although the VA1 signal with the DI mutant is slightly higher in this experiment than that obtained with the wild-type, this is also true of the HSV -CAT control, suggesting sample overloading; in several repeats, we observe no consistent difference between the DI mutant and wild-type p53 in these assays. In contrast, deletion of any one of conserved regions II -V prevents p53 from repressing VA1. Western blot analysis of lysates from transfected cells confirms that the inactivity of these mutants is not due to lack of expression, since each is expressed at a comparable level to the wild-type p53 ( Figure 1b , bottom two panels). These data demonstrate that the central core domain of p53 is necessary for it to regulate a pol III promoter.
The N-terminal region of p53 contributes to the control of pol III transcription
Having established that the central region of p53 is required for it to repress the VA1 gene, we next asked whether sequences outside this core domain are also involved. To begin to address this, we used recombinant p53 protein that was expressed in Sf9 cells using a baculovirus vector. The recombinant p53 carries a polyhistidine tag, which allowed its affinity-purification to near homogeneity ( Figure 2a ). When titrated into a nuclear extract, wild-type p53 produced a clear repression of VA1 transcription ( Figure 2b , lanes 1 -3). In contrast, no inhibition was observed using an equal amount of mutant p53(67 -363), which is missing the N-terminal 66 residues and the C-terminal 29 residues (Figure 2b , lanes 4 -6). This demonstrates that the regulation obtained with full-length p53 is a specific effect and further suggests that control of pol III activity requires sequences outside the central core domain. The mutant p53(1 -363), in which just the Cterminal 29 residues are deleted, was found to retain the ability to repress VA1 gene transcription ( Figure  2b , lanes 7 -9). In contrast, deletion of residues 1 -23 in the mutant p53(24 -392) was found to be sufficient to inactivate p53 in this assay (Figure 2b , lanes 10 -13). It is important to note that the central core domain remains intact and in the wild-type conformation in all of the mutants tested in this experiment; this was confirmed by immunoprecipitation with conformation-sensitive monoclonal antibodies (data not shown). This result suggests that sequences near the N-terminus contribute to pol III repression by p53. Figure 1 showed that VA1 regulation does not require conserved region I, which consists of residues 13 -19. However, the adjacent sequence has been shown to be important for transcriptional control of a variety of pol II promoters (Fields and Jang, 1990; Raycroft et al., 1990) . Indeed, residues 22 and 23 are important for binding TFIID, a function that contributes to the regulation of pol II templates (Chang et al., 1995; Farmer et al., 1996a,b; Lin et al., 1994; Lu and Levine, 1995; Thut et al., 1995) . We therefore examined whether these residues are also involved in regulating VA1 expression. In support of this, we found that full-length p53 carrying a double substitution at positions 22 and 23 was less efficient at VA1 inhibition than the wild-type protein when transfected into SAOS2 cells (Figure 3 ). Western analysis confirmed that this double substitution did not compromise expression of the mutant in the transfected cells. We conclude that efficient repression by p53 of pol III transcription from the VA1 promoter requires an N-terminal sequence that includes amino acids 22 and 23 but excludes residues 13 -19.
The C-terminal domain of p53 contributes to the control of pol III transcription
We have shown previously that the ability to regulate pol III transcription can be blocked specifically if p53 is preincubated with the monoclonal antibody DO-1 was transcribed using HeLa nuclear extract (15 mg) that had been preincubated for 10 min at 308C without addition (lanes 1, 4, 7, 10 and 13), or with the addition of 0.6 mg or 1.2 mg of wild-type p53 (lanes 2 and 3, respectively), 0.6 and 1.2 mg of p53(67 -363) (lanes 5 and 6, respectively), 0.6 and 1.2 mg of p53(1 -363) (lanes 8 and 9, respectively), or 0.6 and 1.2 mg of p53(24 -392) (lanes 11 and 12, respectively) Cairns and White, 1998) . This is consistent with our conclusion that the N-terminal domain of p53 is required for pol III repression, since DO-I recognizes residues 11 -25. Figure 4 shows an experiment in which a similar approach was taken using antibodies that bind to either the central core (pAb1620) or the Cterminal region of p53 (pAb421). In both cases, preincubation with the antibody prevented repression of pol III transcription. As a control for specificity, we tested an equal amount of monoclonal antibody pAb1801, which binds human p53 but does not recognize the murine p53 used in this experiment; repression was not blocked by this negative control. The effect of pAb1620 is consistent with the deletion analysis described in Figure 1 and suggests that the central core of p53 is required for pol III regulation in vitro, as it is in vivo.
Since residues 371 -380 are recognized by pAb421, the ability of this antibody to prevent repression suggests that the C-terminal domain of p53 may be involved in controlling pol III activity. However, this function is not prevented by deletion of residues 364 -392 (Figure 2b) . A possible explanation for this apparent contradiction might be that pAb421 induces a conformational change elsewhere in p53 that influences its ability to regulate pol III. Indeed, binding of pAb421 is known to affect the function of the central core domain (Hupp et al., 1992) . Alternatively, the bound antibody might interfere with some activity performed by the adjacent part of the C-terminal region, that does not require residues 364 -392. To test for such an activity, we investigated the effect on VA1 expression of an extensive truncation that removes all p53 sequence between residue 291 and the C-terminus, but leaves the core domain intact. The truncated mutant is expressed efficiently in SAOS2 cells, but was found to have lost the ability to repress a cotransfected VA1 gene ( Figure 5 ). This observation suggests that the C-terminal domain of p53 does indeed contribute to pol III regulation.
To test further for an involvement of the Cterminal domain in pol III repression in vivo, we examined the effect of a quadruple substitution (ALAL) in residues 365, 372, 379 and 387. This mutant has constitutive DNA-binding activity and can efficiently transactivate pol II transcription and induce G1 arrest or apoptosis (Marston et al., 1998) . Flow cytometry of propidium iodide-stained cells confirmed that the ALAL mutant can indeed provoke G1 arrest in the SAOS2 cells used in our experiments (Figure 6a) . Nevertheless, the ALAL mutation was found to compromise the ability of p53 to repress the VA1 promoter (Figure 6b ). This result provides further evidence that the C-terminal domain of p53 contributes to pol III regulation. In addition, it provides an important demonstration that the repression observed in vivo is not an indirect effect of cell cycle arrest. We conclude that the pol III control function of p53 requires distinct domains that span much of the molecule. Figure 4 Repression of pol III transcription by p53 can be blocked specifically using antibodies against the central core or C-terminal domains. pVA1 (250 ng) was transcribed using HeLa nuclear extract (15 mg) that had been preincubated for 10 min at 308C in the presence of buffer (lane 1) or 1 mg of wild-type p53 (lanes 2 -5). Prior to use, the p53 was incubated at 48C for 2 h in the presence of buffer (lane 2), or 0.5 mg of pAb1801 (lane 3), pAb421 (lane 4) or pAb1620 (lane 5) Domains used by p53 to repress pol III transcription T Stein et al
Discussion
Our data indicate that at least three regions of p53 are involved in the efficient repression of pol III transcription; N-terminal sequences that include residues 22 and 23, the central core domain, and a region towards the C-terminus of the protein. However, residues 13 -19 and 364 -392 can be dispensed with. It is therefore apparent that the repression of pol III transcription involves much, but not all, of the p53 molecule.
The consensus DNA sequence that is recognized by p53 is not found associated with most of the genes that it inhibits. Although it is difficult to exclude the possibility of low-affinity non-consensus binding sites, it is likely that p53 regulates such genes by proteinprotein interactions, rather than direct recognition of DNA. We believe this to be the case for pol III transcription, since p53 can repress every pol III template tested, although the only sequences shared by all these genes are the promoter and terminator elements that are recognized by the basal pol III machinery. In these cases, p53 appears to influence expression by binding to TFIIIB, a factor that is essential to recruit pol III to its templates (Cairns and White, 1998; Chesnokov et al., 1996) . It is therefore perhaps unexpected that the sequence-specific DNAbinding domain of p53 is required for repression of pol III transcription. Nevertheless, our data show clearly that deletions within this central core domain abolish completely the ability to regulate VA1 expression in vivo (Figure 1) . Furthermore, repression in vitro can be blocked by antibody pAb1620, which binds to the p53 core. It will be interesting to establish the role played by this region in controlling pol III activity. An obvious possibility is that central deletions or antibody binding interfere with repression by disrupting the conformation of the p53 molecule. Alternatively, this Figure 5 Deletion of the C-terminal 102 residues of p53 abolishes its ability to repress pol III transcription. SAOS2 cells were cotransfected with pVA1 (3 mg), HSV -CAT (3 mg) and 2 mg of empty vector (lane 1), or vector encoding wild-type p53 (lane 2) or p53D291 (lane 3). RNA and protein were isolated 48 h after transfection. The upper and middle panels show primer extension analyses of extracted RNA using primers specific for VA1 (upper panel) and CAT (middle panel). The lower panel shows a Western blot of extracted protein using anti-p53 antibody DO-1 Figure 6 A C-terminal domain p53 substitution mutant retains the ability to induce G1 arrest but cannot repress pol III transcription. SAOS2 cells were cotransfected with pVA1 (3 mg), HSV -CAT (3 mg) and 2 mg of empty vector (lane 1), or vector encoding wild-type p53 (lane 2) or p53ALAL (lane 3). The bar chart reveals the G0/G1 phase content after 30 h as revealed by flow cytometry after propidium iodide staining. RNA and protein were isolated 48 h after transfection. The upper and middle panels show primer extension analyses of extracted RNA using primers specific for VA1 (upper panel) and CAT (middle panel). The lower panel shows a Western blot of extracted protein using anti-p53 antibody DO-1 Domains used by p53 to repress pol III transcription T Stein et al domain might provide a docking site for TFIIIB or a hypothetical cofactor that may contribute to regulation. Further experiments will be carried out to distinguish these possibilities. The ability of p53 to inhibit VA1 is compromised by deletions at either end of the protein. This is reminiscent of the situation for pol II transcription, where both the N-and C-terminal regions of p53 have been shown to function in transcriptional repression (Horikoshi et al., 1995; Sang et al., 1994; Subler et al., 1994) . A potential explanation is offered by the fact that the N-and C-terminal domains of p53 both interact with TBP, the TATA-binding protein (Horikoshi et al., 1995) . TBP is an essential component of the TFIIIB complex (Kassavetis et al., 1992; Lobo et al., 1992; Simmen et al., 1992; Taggart et al., 1992; . Furthermore, functional TBP is required for titration of excess TFIIIB to relieve repression of VA1 by p53 in vitro (Cairns and White, 1998) . It is therefore plausible that p53 binds and represses TFIIIB by interacting directly with its TBP subunit; this might require the TBP-binding functions located in the N-and C-terminal domains of p53 (Horikoshi et al., 1995) . An alternative explanation is suggested by the finding that both these regions also bind to the corepressor mSin3a, which can inhibit pol II transcription by recruiting histone deacetylases (Murphy et al., 1999) . Expression of pol III-transcribed genes in vivo can be influenced strongly by histone deacetylase activity (Sutcliffe et al., 2000) . These observations raise the possibility that p53 might repress pol III templates by binding to TFIIIB and recruiting histone deacetylases via mSin3a.
An apparent anomaly exists between the various lines of evidence that implicate the C-terminal domain of p53 in pol III control. Transcriptional repression can be blocked by pAb421 antibody binding to residues 371 -380 (Figure 4) or by the ALAL quadruple substitution at residues 365, 372, 379 and 387 ( Figure  6b ), but it is not impaired by deletion of residues 364 -392 (Figure 2b ). Both pAb421 and the ALAL mutation have been shown to induce a conformational change that activates DNA binding by p53 (Hupp et al., 1992; Marston et al., 1998) . It is therefore possible that this structural rearrangement is preventing the pol III repression function. Nevertheless, this function is also abolished by deletion of residues 291 -329; this suggests that the C-terminal domain does contribute to pol III control and that the effects of pAb421 and ALAL are not simply due to rearrangements elsewhere in the molecule. Residues 339 -346 were reported to possess autonomous transrepression activity with respect to pol II reporters (Hong et al., 2001) and it is possible that this contributes to the pol III response. Furthermore, an autonomous tetramerization domain is located at residues 325 -356 (Jeffrey et al., 1995; Sturzbecher et al., 1992) and the ALAL mutant is unable to form tetramers. We have attempted to determine the role of oligomerization in the pol III repression function of p53, but have yet to obtain a clear answer, perhaps because several distinct activities map to the same region of this complex molecule. All we can conclude with confidence at present is that VA1 repression requires sequence that lies between residues 291 and 364.
It might be argued that some of the effects we have observed on VA1 expression in transient transfections could be an indirect response to cell cycle arrest. It is certainly the case that pol III transcriptional activity in mammalian cells is repressed during G0 and G1 phases (Abelson et al., 1974; Brown et al., 2000; Mauck and Green, 1974; Scott, 2001; White et al., 1995a) . We have shown recently that this is primarily due to the action of RB. Thus, fibroblasts from RB-knockout mice are severely defective in their ability to down-regulate pol III activity following G0/G1 arrest (Scott et al., 2001 ). Since the current study has used SAOS2 cells, which lack functional RB (Shew et al., 1990) , the G1 arrest that is induced by p53 might have a minimal effect on the pol III machinery. Indeed, the ALAL mutant induces G1 arrest in SAOS2 cells and yet is unable to repress VA1 effectively. These observations demonstrate that G1 arrest in these RB-negative cells is insufficient to inhibit pol III transcription and eliminate the suspicion that p53 is working indirectly through an effect on the cell cycle. We believe that p53 exerts its effect by interacting directly with TFIIIB; a direct effect is supported strongly by the fact that p53 also represses pol III activity in vitro.
It is very well documented that a wide range of transformed and tumour cell types display abnormally high levels of pol III products (reviewed in White, 1998b) . This phenomenon may be partially explained by our unexpected finding that the DNA-binding core domain is essential for repression of pol III transcription in vivo, even though this regulation appears not to involve sequence-specific DNA recognition. Mutations in p53 are found in about half of all human tumours and in most of these cases the mutations localize to the central core domain of the protein (Hollstein et al., 1994) . This suggests that TFIIIB will be released from repression in many cancers carrying p53 mutations, just as we have shown previously in fibroblasts derived from p53-knockout mice (Cairns and White, 1998) . Indeed, we have recently obtained evidence that the pol III control function can be severely compromised by tumourderived core domain substitutions, such as the R175H 'hot-spot' mutation (Stein et al., 2002) . Such effects are likely to contribute significantly to the abnormal elevation of pol III activity that is so frequently observed in human cancers White, 1998b) .
Materials and methods

Plasmids
The pVA1 plasmid contains the adenovirus VA1 gene (Dean and Berk, 1988) . HSV -CAT contains the CAT gene driven by the thymidine kinase promoter of herpes simplex virus. All p53 expression constructs have been described previously.
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The p53DI -p53DV series have each had a conserved region deleted, as follows: p53DI, residues 13 -19 deleted, p53DII, residues 117 -142 deleted; p53DIII, residues 171 -181 deleted; p53DIV, residues 234 -258 deleted; p53DV, residues 270 -286 deleted (Crook et al., 1994) . pRC/CMV -SN22/23 carries a double substitution at residues 22 and 23 (Lin et al., 1994) . p53D291 encodes p53 with the C-terminal 102 residues deleted (Crook et al., 1994) . Mutant p53ALAL carries substitutions in residues 365, 372, 379 and 387 (Sturzbecher et al., 1992) .
Cell culture and transfection
The human osteosarcoma cell line SAOS2 was cultured in Dulbecco's modified Eagle medium (DMEM) with 10% foetal calf serum. Cells were transiently transfected using the calcium-phosphate precipitation method. DNA precipitates were left on the plates overnight and then the cells were washed with PBS and cultured for 48 h before harvesting. Total RNA was extracted using TRI reagent (Sigma), according to the manufacturer's instructions. It was then analysed by primer extension using both VA1-specific (5'-CACGCGGGCGGTAACCGCATG-3') and CAT-specific (5'-CGATGCCATTGGGATATATCA-3') labelled primers. Primer extension reactions were conducted as previously described (White et al., 1996) .
FACS analysis
SAOS2 cells (10 6 ) seeded in a 100 mm dish were transfected with 10 mg of the indicated p53 expression vectors or empty vector together with 8 mg of pCMV -CD20. After 30 h, cells were harvested in cell dissociation buffer (Sigma) and incubated with FITC-conjugated CD20 antibody (Becton Dickinson) to identify the transfected cell population. The cells were then washed in PBS and fixed overnight at 48C in 50% ethanol/PBS. Cells were washed again and treated with RNaseA (25 U/ml) and propidium iodide solution (10 ng/ml) for 20 min at 48C. Cells were sorted on a FACScan cell sorter (Becton Dickinson) and analysed using the Cell Quest Software package. Approximately 10 5 cells expressing CD20 were counted.
Preparation of proteins and transcription assays
Construction of recombinant baculovirus encoding Histagged versions of p53 has been described (Okorokov and Milner, 1999) . Recombinant p53 was expressed in Sf9 insect cells and then affinity-purified as previously described (Molinari et al., 1996; Okorokov et al., 1997) . Transcription reactions were carried out as previously (White et al., 1989) , except that pBR322 was not included and the incubations were for 60 min at 308C. HeLa nuclear extract was purchased from the Computer Cell Culture Center (Mons, Belgium).
Antibodies and Western blotting
Western immunoblot analysis was performed as previously described (White et al., 1995b) using anti-p53 antibody DO-1 (Santa Cruz) or PAb421 (Calbiochem). pAb1801 and pAb1620 were obtained from Calbiochem.
